Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BCTX with free AI briefings, catalyst countdowns, and dilution alerts.

BCTX · BriaCell Therapeutics Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$20.5M Cash on Hand
9.5mo Cash Runway
9.3% Short Interest
Follow BCTX by email Get an email when BCTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BCTX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic GM-CSF-secreting Breast Cancer… Breast Cancer Phase 3 · NCT06072612 Recruiting
BC1 cell line Breast Cancer Phase 1/2 · NCT06471673 Unknown
Bria-OTS regimen and CPI (tislelizumab) Breast Cancer Phase 1/2 · NCT06471673 Unknown

Also used in these trials (approved or third-party drugs, not BCTX's own candidates): Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Interferon Inoculation, Recombinant Interferon Alfa-2b.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BCTX holds $20.5M in cash and short-term investments (as of Jul 31, 2026) and burns about $6.5M/quarter from operations, an estimated runway of 9.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCTX files for a raise →

👥 Who Owns BCTX

Insiders 29.1% Institutions 9.8% Public and other holders 61.1%
HolderTypeShares% of sharesAs of
Marc Lustig
Director, 10% owner · +902,935 options
Insider 2,542,935 29.12% 2024-05-14
Kenneth Griffin Institution (13G, 5%+) 717,198 8.21% 2026-01-15
Iridian Asset Management LLC Institution (13F) 65,000 0.74% 2026-09-30
HRT Financial LP Institution (13F) 35,248 0.40% 2026-09-30
Jane Street Group, LLC Institution (13F) 21,734 0.25% 2026-09-30
Citadel Advisors Llc Institution (13F) 10,432 0.12% 2026-09-30
National Bank of Canada/FI/ Institution (13F) 2,172 0.02% 2026-09-30
Federation Des Caisses Desjardins Du Que Institution (13F) 450 0.01% 2026-09-30
Morgan Stanley Institution (13F) 420 0.00% 2026-09-30
UBS Group AG Institution (13F) 373 0.00% 2026-09-30
Allworth Financial LP Institution (13F) 100 0.00% 2026-09-30

Share count 8,732,381 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BCTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.